Market Overview

Perrigo Buys Remaining Stake in Cobrek Pharma for ~$45M

Related PRGO
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Benzinga's Top Upgrades
Tracking Ruane, Cunniff & Goldfarb's Portfolio - Q3 2015 Update (Seeking Alpha)

Perrigo Company (Nasdaq: PRGO) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately-held, Chicago, Illinois-based drug development company, for approximately $45 million on a cash free and debt free basis.

Posted-In: News M&A


Related Articles (PRGO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters